GDPD4 Inhibitors

The chemical class referred to as GDPD4 inhibitors includes a variety of compounds that, by intervening in different aspects of cellular metabolism, can indirectly modulate the activity of GDPD4. These compounds do not target GDPD4 directly but instead exert their influence by altering the lipid environment in which GDPD4 operates or by modifying signaling pathways that can impact its function. For instance, Miltefosine and Perhexiline can change the lipid composition, which may affect the membrane association and substrate accessibility for GDPD4, thereby influencing its enzymatic activity.

Other compounds in the list, such as Manumycin A and Genistein, affect protein prenylation and tyrosine kinase activity, respectively. These processes are essential for proper localization and function of numerous proteins involved in lipid metabolism, including GDPD4. Additionally, inhibitors like D609 and U73122 target specific phospholipases, which are directly involved in generating substrates for GDPD4, suggesting that these inhibitors can alter the substrate pool available to GDPD4. Compounds such as Etomoxir and Triacsin C modify fatty acid metabolism, which is intricately linked to the lipid signaling pathways that GDPD4 is part of. Lastly, GW4869 and Imipramine affect sphingolipid metabolism, which can have downstream effects on GDPD4's activity due to the interconnected nature of lipid metabolic pathways.